The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
18 years at the time of informed consent
Ability to provide written informed consent and HIPAA authorization.
Eastern cooperative group (ECOG) performance status of 0 to 2
Newly diagnosed histologically or cytologically confirmed stage IV Non-Small Cell Lung Cancer (NSCLC). Patients with locally advanced NSCLC that are not candidates for definitive therapy but are candidates for trial are allowed per investigator discretion.
Self-reported weight loss of > 10% in the 6 weeks prior to study entry
History of symptomatic hypoglycemia or uncontrolled diabetes
Prior therapies with inhibitors of insulin growth factor I(IGF-1) such as Linsitinib or Picropodophyllin
Concurrent use of somatostatin
VA Office of Research and Development
Lead sponsor
Indiana University
Collaborator
US Department of Veterans Affairs Cooperative Studies Program
Collaborator
L-Nutra Inc
Collaborator